Insider Transactions in Q1 2022 at Mirati Therapeutics, Inc. (MRTX)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 11
2022
|
Henry J Fuchs |
SELL
Open market or private sale
|
Direct |
11,000
-24.64%
|
$1,155,000
$105.63 P/Share
|
|
Feb 11
2022
|
Henry J Fuchs |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+28.0%
|
$220,000
$20.54 P/Share
|
|
Jan 19
2022
|
Julie M Cherrington |
SELL
Open market or private sale
|
Direct |
1,475
-36.68%
|
$171,100
$116.07 P/Share
|
|
Jan 18
2022
|
Benjamin Hickey EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
627
-1.76%
|
$75,240
$120.48 P/Share
|
|
Jan 18
2022
|
Charles M Baum Founder, President, and CEO |
SELL
Open market or private sale
|
Direct |
2,517
-1.93%
|
$302,040
$120.48 P/Share
|
|
Jan 18
2022
|
Charles M Baum Founder, President, and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,703
+2.76%
|
$99,981
$27.0 P/Share
|
|
Jan 18
2022
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
627
-0.71%
|
$75,240
$120.51 P/Share
|
|
Jan 18
2022
|
Vickie S Reed SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
533
-3.35%
|
$63,960
$120.48 P/Share
|
|
Jan 14
2022
|
Shalini Sharp |
BUY
Grant, award, or other acquisition
|
Direct |
2,546
+33.87%
|
-
|
|
Jan 14
2022
|
Aaron I. Davis |
BUY
Grant, award, or other acquisition
|
Direct |
2,546
+5.58%
|
-
|
|
Jan 14
2022
|
Julie M Cherrington |
BUY
Grant, award, or other acquisition
|
Direct |
2,546
+38.77%
|
-
|
|
Jan 14
2022
|
David D. Meek Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,057
+50.0%
|
-
|
|
Jan 14
2022
|
Maria E Martinez |
BUY
Grant, award, or other acquisition
|
Direct |
2,546
+29.72%
|
-
|
|
Jan 14
2022
|
Craig A Johnson |
BUY
Grant, award, or other acquisition
|
Direct |
2,546
+29.72%
|
-
|
|
Jan 14
2022
|
Henry J Fuchs |
BUY
Grant, award, or other acquisition
|
Direct |
2,546
+29.72%
|
-
|
|
Jan 14
2022
|
Bruce L A Carter |
BUY
Grant, award, or other acquisition
|
Direct |
2,546
+29.72%
|
-
|
|
Jan 14
2022
|
Faheem Hasnain |
BUY
Grant, award, or other acquisition
|
Direct |
3,619
+29.34%
|
-
|
|
Jan 14
2022
|
Benjamin Hickey EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,755
+23.2%
|
-
|
|
Jan 14
2022
|
Charles M Baum Founder, President, and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
25,543
+16.78%
|
-
|
|
Jan 14
2022
|
Jamie Christensen EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,755
+10.88%
|
-
|
|
Jan 14
2022
|
Vickie S Reed SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,377
+25.27%
|
-
|
|
Jan 07
2022
|
Vickie S Reed SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
345
-3.17%
|
$46,575
$135.94 P/Share
|
|
Jan 07
2022
|
Benjamin Hickey EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,964
-7.33%
|
$265,140
$135.94 P/Share
|
|
Jan 04
2022
|
Vickie S Reed SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
758
-6.52%
|
$111,426
$147.74 P/Share
|
|
Jan 04
2022
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,442
-1.83%
|
$211,974
$147.72 P/Share
|
|
Jan 04
2022
|
Charles M Baum Founder, President, and CEO |
SELL
Open market or private sale
|
Direct |
4,114
-1.96%
|
$608,872
$148.41 P/Share
|